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Available online xxxxBackground: Chronic inﬂammation caused by ulcerative colitis (UC) causes a pro-neoplastic drive in the inﬂamed
colon, leading to amarkedly greater risk of invasivemalignancy compared to the general population. Despite sur-
veillance protocols, 50% of cases proceed to cancer before neoplasia is detected. The Enhanced Neoplasia Detec-
tion and Cancer Prevention in Chronic Colitis (ENDCaP-C) trial is an observational multi-centre test accuracy
study to ascertain the role of molecular markers in improving the detection of dysplasia. We aimed to validate
previously identiﬁed biomarkers of neoplasia in a retrospective cohort and create predictivemodels for later val-
idation in a prospective cohort.
Methods: A retrospective analysis using bisulphite pyrosequencing of an 11 marker panel (SFRP1, SFRP2, SRP4,
SRP5,WIF1, TUBB6, SOX7, APC1A, APC2,MINT1, RUNX3) in samples from35patientswith cancer, 78with dysplasia
and 343 without neoplasia undergoing surveillance for UC associated neoplasia across 6 medical centres. Predic-
tive models for UC associated cancer/dysplasia were created in the setting of neoplastic and non-neoplastic mu-
cosa.
Findings: For neoplastic mucosa a ﬁvemarker panel (SFRP2, SFRP4, WIF1, APC1A, APC2) was accurate in detecting
pre-cancerous and invasive neoplasia (AUC= 0.83; 95% CI: 0.79, 0.88), and dysplasia (AUC= 0.88; (0.84, 0.91).
For non-neoplastic mucosa a four marker panel (APC1A, SFRP4, SFRP5, SOX7) had modest accuracy (AUC= 0.68;
95% CI: 0.62,0.73) in predicting associated bowel neoplasia through the methylation signature of distant non-
neoplastic colonic mucosa.
Interpretation: This multiplex methylation marker panel is accurate in the detection of ulcerative colitis associ-
ated dysplasia and neoplasia and is currently being validated in a prospective clinical trial.
Funding: The ENDCAP-C study was funded by the National Institute for Health Research Efﬁcacy andMechanism
Evaluation (EME) Programme (11/100/29).
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Chronic inﬂammation caused byUlcerative Colitis (UC) causes a pro-
neoplastic drive in the inﬂamed colon, leading to amarkedly greater risk
of invasive malignancy compared to the general population [1]. Al-
though rates of UC associated neoplasia seem to be decreasing [2], due
in part to improved medical control of inﬂammation, there remains anomic Science, Vincent Drive,
. This is an open access article under
ta, J.J. Deeks, et al., Validation
oi.org/10.1016/j.ebiom.2018.1signiﬁcant risk beyond the background risk of colorectal cancer (CRC).
The risk is particularly pronounced in patients with extensive colitis
and an inﬂammatory bowel disease (IBD) diagnosis before 30 years of
age [3].
Despite colonoscopic surveillance protocols [4], 50% of cases are re-
ported to have developed invasive cancer before neoplasia is detected.
The disease is frequently multifocal, presumed due to the diffuse sensi-
tisation of the large bowelmucosa by the chronic inﬂammatory process.
Mutational events, such as KRAS and TP53mutation [5] have been ob-
served as part of this ﬁeld cancerization effect in UC, however no consis-
tent pattern has been demonstrated.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Research in context
Evidence before this study
• Chronic ulcerative colitis carries a substantially elevated risk of neo-
plasia as compared to an age matched unaffected population
• Current methods for detection of dysplasia and early neoplasia
are unreliable
• Epigenetic markers have previously shown promise in the de-
tection of UC associated dysplasia and neoplasia.
Added value of this study
• Methylation at a ﬁve marker panel (SFRP2, SFRP4, WIF1, APC1A,
APC2) panel highly accurately detects ulcerative colitis associated
dysplasia and cancer in a retrospective cohort from patients treated
at 6 different hospitals in the UK
• A second methylation panel ((APC1A, SFRP4, SFRP5, SOX7) may
have value as an adjunct to colonoscopy in identifying high
risk patients by providing predictive markers in random biop-
sies of background mucosa.
Implications of all the available evidence
• A multi-marker methylation panel may be able to identify patients
with high risk dysplasia
2 A.D. Beggs et al. / EBioMedicine xxx (2018) xxxEndoscopic therapy can provide local control of early dysplastic
lesions, but enhanced detection strategies are required to aid early de-
tection and ensure that progressive dysplasia is not missed during sur-
veillance [6–8].
Chronic inﬂammation has been demonstrated to promote aberrant
DNA methylation in conditions such as ulcerative colitis [9]. This may
be due to a direct chemical effect causing cytosinemethylation in the in-
ﬂamed colon. Use of abnormal DNA methylation as a biomarker for ul-
cerative colitis associated neoplasia has considerable theoretical
advantages; ﬁrstly methylation tends to be gene-centric [10], centering
around CpG islands and secondly it is usually homogenously distributed
within the CpG island, having a functional effect on transcription factor
binding and thus gene expression. This homogeneity facilitates simpler
detection of abnormal methylation patterns. Another advantageous
property of assaying methylation is that it tends to occur as part of a
“ﬁeld cancerization” effect [11] whereby associated changes in methyl-
ation extend out past the dysplastic lesion in the colon and thus can be
detected in apparently normal mucosa some distance from the lesion
[12,13].
It has been demonstrated that hypermethylation of members of the
Frizzled pathway, involved in Wnt signalling regulation, are associated
with colorectal tumouriogenesis [14–16]. Dhir et al. [17] carried out an
analysis of methylation of Wnt signalling genes (APC1A, APC2, SFRP1,
SFRP2, SFRP4, SFRP5, DKK1, DKK3, WIF1 and LKB1) in the development
of UC associated neoplasia, ﬁnding that methylation of SFRP1/2 and
APC1A/2 were associated with the progression to invasive disease. Guo
et al. [18] demonstrated that SOX7, an independent checkpoint for
beta-catenin function can be hypermethylated in colorectal cancer and
may play a role in UC associated neoplasia.
Genetic variation in RUNX3 has been demonstrated as a risk factor
for the development of ulcerative colitis [19] and Garritty-Park et al.
[20] demonstrated that hypermethylation of RUNX3, and MINT1 couldPlease cite this article as: A.D. Beggs, S. Mehta, J.J. Deeks, et al., Validation
module 1 of the E..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.1be detected in the non-neoplastic mucosa from patients with colitis as-
sociated neoplasia. In our own analysis of colitis associated mucosa [21]
utilising the IlluminaMethylation450 platform, we identiﬁed an associ-
ation between hypomethylation of TUBB6 in non-neoplastic colonic
mucosa from patients with UC associated neoplasia.
In the Enhanced Neoplasia Detection and Cancer Prevention in
Chronic Colitis (ENDCaP-C) study, we set out to establish whether an
optimised methylation marker panel of suitable speciﬁcity could im-
prove detection of early neoplastic lesions at colonoscopic surveillance
diagnostic accuracy. This initial phase (Module 1) aims to measure the
accuracy of an optimised panel of markers on a multicentre, retrospec-
tive cohort of patients with ulcerative colitis before assessing their util-
ity in a prospective multi-centre test accuracy study (Module 3).
We aimed to:
1) Establish and optimise amulti-markermethylation panel for the de-
tection of colitis associated neoplasia.
2) Measure the accuracy of this panel in a retrospectivemulticentre co-
hort of patients with colitis associated neoplasia.2. Materials & methods
2.1. Patient recruitment
Patients were identiﬁed from archived histology biopsy samples in 6
hospitals across the West Midlands area. Patients were identiﬁed
through tracing endoscopy records and correlation with histology
reports. Searches were restricted to endoscopies after January 1996, be-
cause of changes to formalin ﬁxation at that time, and before January
2014 to minimise missed neoplasia through identiﬁcation during the
follow up period. Mucosal biopsies were classiﬁed via pathological
examination using H&E sections as either neoplasia, deﬁned as any of
adenocarcinoma, high-grade or low-grade dysplasia; matched non-
neoplastic deﬁned as non- neoplastic chronically inﬂamed colonic
mucosal biopsies taken distant from areas of neoplasia as distant as pos-
sible from the original neoplastic region (see Fig. 1); control deﬁned as
colonic mucosa, sampled from patients with chronic ulcerative colitis
of duration N8 years and extending to the splenic ﬂexure or beyond
OR patientswith a diagnosis of both UC and PSCwhohad been screened
for neoplasia without it being found and in whom no neoplasia was
seen in follow up after the biopsy was taken. Ethical approval was
from South Birmingham Research Ethics Committee (Ref: 08/H1207/
104).2.2. Sample processing
Biopsy samples from identiﬁed patients were retrieved from the his-
topathology archives at the 6 collaborating hospitals. For those patients
with neoplasia in the large bowel, separate biopsies from different co-
lonic segmentswere selected alongside the neoplastic biopsy. All blocks
underwent central histological review by PT, with representative sec-
tions undergoing DNA extraction. Dysplasia was deﬁned as any of al-
tered nuclear/cytoplasmic ratio, increased cell size and/or an increase
inmitotic ﬁgures. DNA extraction of neoplasiawas performed by needle
macrodissection to enrich for tumourmaterial, andmacrodissectedma-
terial was extracted using the FFPE protocol of the Qiagen DNEasy FFPE
kit (Qiagen, UK). Extracted DNA was quantiﬁed by both Nanodrop
spectrophotometry and Qubit ﬂuorimetry.
Neoplasia, matched non-neoplastic and control samples were in-
cluded in mixed batches to ensure that test performance could be
analysed at sequential analyses across the study duration. Each sample
was labelled with only a study sample identiﬁcation number and assays
undertaken blinded to neoplasia status.of epigenetic markers to identify colitis associated cancer: Results of
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Fig. 1. Diagram of colonoscopic sampling from patients for ENDCAP-C study.
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500 ng of extracted DNA was bisulphite converted using a Zymo
EZ-DNA methylation bisulphite conversion kit according to the manu-
facturer's protocol. Two microliters of eluted bisulphite converted
DNA was utilised in a pyrosequencing PCR reaction using the Qiagen
PyroMark PCR kit according to themanufacturer's protocol in a 25uL re-
action volume. PCR products were run on a 2% agarose gel with a DNA
size ladder and successful ampliﬁcation was deﬁned as the presence of
a band at the appropriate size for the marker run. PCR products were
cleaned using streptavidin beads, washed and mixed with the requisite
pyrosequencing primers. These were then sequenced on a Qiagen
PyroMark Q96 instrument. All reactions were run with 100% methyl-
ated and unmethylated DNA positive and negative controls, as well as
a water reaction. Methylated DNA was generated by incubating 1μg of
blood derived control DNA with M.Ssi CpG methyltransferase (New
England Biolabs). Unmethylated DNAwas generated by whole genome
ampliﬁcation of 10 ng of blood derived control DNA using the Qiagen
Repli-G Mini kit.
Themarker panel chosen for this experimentwas based on previous
ﬁndings and consisted of the following markers: SFRP1, SFRP2, SFRP4,
SFRP5, WIF1, TUBB6, SOX7, APC1A, APC2, MINT1, RUNX3. Primer se-
quences, chromosomal positions and reaction conditions are shown in
Supplementary Table 1. After each run, sample data was examined
using Qiagen PyroMark Q96 software. Samples that had failed Qiagen
quality metrics were marked as failed on the sample sheet.
2.4. Sample size
The original planned sample size of 160 neoplastic and 320 control
samples was determined to provide adequate events to robustly de-
velop a model (with N10 events per marker) and provide estimates of
sensitivity and speciﬁcitywith adequate precision (with 95% conﬁdence
interval width b16% for sensitivity and b12% for speciﬁcity). The 2:1
sampling ratio is determined based on access to sample banks.
2.5. Statistical analysis
Where biomarkers were examined at multiple CpG sites the mean
CpG value across sites was used in all analyses for consistency and as
methylationwithin small regions tends to be distributed homogenously
[10]. Statistical analysis was then undertaken in three steps.
First, results for each batch of samples for each of the 11 biomarkers
(SFRP1, SFRP2, SFRP4, SFRP5, WIF1, TUBB6, SOX7, APC1A, APC2, MINT1,
RUNX3.) were evaluated in a group sequential analysis following the
O'Brien and Fleming (OBF) method [22], to assess whether further
testing of each biomarker was justiﬁed or considered futile. Sequential
boundaries were constructed according to the OBF method, thePlease cite this article as: A.D. Beggs, S. Mehta, J.J. Deeks, et al., Validation
module 1 of the E..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.1t-statistic computed for each biomarker at each analysis step, and com-
parison made to the predeﬁned boundary values to test for statistical
signiﬁcance or futility (see Supplementary Fig. 1).
In this ﬁrst stage the distributions of the biomarker values were un-
known, and data were analysed without transformation. Once all data
were accumulated, visual inspection of histograms demonstrated posi-
tive skew (Supplementary Fig. 2), and the mean biomarker values for
each sample were log-transformed prior to further analysis.
In the second stage markers with responses suitable for inclusion in
the predictive models were selected. The ability of each marker to dis-
criminate was described by computing the ratio of geometric means
(with 95% conﬁdence interval) and statistical signiﬁcance was assessed
by two-sample t-tests undertaken on the log transformed scale. Com-
parisons were made [1] between neoplasia samples and control
samples, and [2] between matched non-neoplastic samples and
control samples. Biomarkers which showed signiﬁcant discrimination
(p b 0.05) and with ampliﬁcation rates N85% were included in the pre-
dictive model.
In stage 3 predictive models were ﬁtted using logistic regression
with outcome (1 = Sample or 0 = Control) and the mean log CpG
value for each patient for the biomarkers selected in Stage 2. Only sam-
ples which had complete data for the selected biomarkers were initially
included in these analyses. Three separatemodelswere constructed: [1]
differentiating neoplasia samples from control samples; [2] differentiat-
ing dysplasia samples from control samples; and [3] differentiating
matched non-neoplastic samples from control samples. Model 2 used
the same patients and biomarker selection as Model 1, but excluded
any samples which were classed as adenocarcinomas.
Discriminatory performance for each model was measured by the
area under the ROC curve (AUC). We estimated optimism by ﬁtting
the predictedmodel in 100 bootstrap samples and computing the aver-
age difference between the AUC in the bootstrap samples and in the
original data. We applied the computed shrinkage factor to the param-
eter estimates [23]. The ﬁnal models were produced including all sam-
ples, using multiple imputation using chained equations to impute
missing biomarker data. Multiple imputation models used 50 iterations
with pathology categorisation, sample type and measurements of all
other biomarkers as predictors. The model coefﬁcients were corrected
for optimismby application of the shrinkage factor. To facilitate applica-
tion of the model when individual or pairs of biomarkers are unavail-
able, reduced models were computed omitting each biomarker and
possible pair of biomarkers from the multiple imputation model.
One biomarker (TUBB6) was not selected for inclusion in Models 1
and 2 in the stage 1 OBF analysis on untransformed data, but did show
signiﬁcant differences in stage 2 once log transformations had been ap-
plied. Models 1 and 2 were ﬁtted with and without this biomarker.
The clinical team considered that a positive test result should have a
positive predictive value of at least 20% to be of clinical value. Given an
assumed background incidence of 4% this corresponds to the point on
the ROC curve with a positive likelihood ratio (sensitivity/(1-speciﬁc-
ity)) of 6. The threshold at this point was identiﬁed from the ROC tabu-
lation of each predictive equation, and estimates of sensitivity and
speciﬁcity obtained. We also identiﬁed thresholds for each model
which corresponds with 90% of cases being detected.
3. Results
In total, 838 blocks from 575 patients were collected from 6 partici-
pating hospitals. Of these, 269 blockswere not used in the study because
they were duplicates from the same patient, or deemed not useable
after histological review. This left 569 blocks from 456 patients under-
going surveillance, consisting of 113 neoplastic, 113 matched non-
neoplastic and 343 control blocks (Table 1). Of the neoplastic biopsy
samples, 35/113 contained adenocarcinoma and the remaining 78/113
harboured dysplasia only. Baseline data for participants providing
these blocks is shown in Table 2.of epigenetic markers to identify colitis associated cancer: Results of
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Table 1
Samples graded according to histology and inﬂammation (central assessments).
Histopathological type Patients with neoplasia
(n = 113)
Patients without neoplasia
(control) (n = 343)
Total (n = 569)
Neoplastic samples Matched non-neoplastic samples
Number of blocks mean (sd) 2.9 (4.4) 1.2 (0.5) 1.6 (2.3)
Median [IQR] 2 [2–2] 1 [1–1] 1 [1–2]
Range 2–42 1–6 1–42
Adenocarcinoma 35 (31%) – – 35 (6%)
High grade dysplasia 4 (4%) – – 4 (1%)
Low grade dysplasia 74 (65%) – – 74 (13%)
Active chronic inﬂammation – 33 (29%) 83 (25%) 116 (20%)
Non active chronic inﬂammation – 69 (61%) 204 (59%) 273 (48%)
Normal mucosa – 11 (10%) 56 (16%) 67 (12%)
4 A.D. Beggs et al. / EBioMedicine xxx (2018) xxx3.1. Selection of biomarkers
Eight of the eleven methylation markers had an ampliﬁcation
success rate of N85% (Table 3 and Supplementary Table 2). The three re-
maining primer sets were within the promotor regions of SFRP1, MINT1
and RUNX3. Because of the reduced reliability, these 3 were not taken
forward to further analysis.
In the stage 2 analysis, ﬁve markers accurately discriminated be-
tween neoplasia and control samples with p b 0.0001 – SFRP2, SFRP4,
WIF1, APC1A and APC2 (Table 3); with between 40% and 76% increases
in geometric mean values. TUBB6 showed a smaller (31%) increase but
which was also strongly signiﬁcant (p = 0.003).
Comparison in samples of methylation in the background mucosa
(from patients with colitis associated neoplasia) with control patients
(with chronic UC only) showed some discrimination in four of the
eight promotor regions. SFRP4, APC1A, SFRP5 and SOX7 (Table 3). Two
of these markers SFRP4 and APC1A showed increases of 7% and 28% re-
spectively, in geometric mean values; the other two, SFRP5 and SOX7
showed decreases of 23% and 27% respectively.
3.2. Performance of predictive models
Predictive models to discriminate neoplasia samples from controls
had good discrimination (Table 4). The optimism adjusted AUC for
Model 1 detecting all neoplasiawas 0.86 (95% CI 0.81, 0.91) for the com-
plete case analysis (with a shrinkage factor of 0.93) but lower at 0.83
(95% CI 0.79, 0.88) for the model using multiple imputation (Fig. 2A).
Addition of TUBB6 only increased the AUC by 0.001. When consideredTable 2
Baseline patient data.
Baseline characteristics
Montreal classiﬁcation Distal (Recto-Sigmoid)
Left-sided (to splenic ﬂexure)
Extensive (beyond splenic ﬂexure)
Unknown/Missing
Smoker No
Yes
Unknown
Ex-smoker
Primary sclerosing cholangitis No
Yes
Unknown/Missing
Family history of inﬂammatory bowel disease No
Yes
Unknown/Missing
Family history of colorectal cancer No
Yes
Unknown
Missing
Please cite this article as: A.D. Beggs, S. Mehta, J.J. Deeks, et al., Validation
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independent predictive value.
Discrimination of Model 2 predicting only dysplasia (excluding ade-
nocarcinoma cases) was higherwith an optimism corrected AUC of 0.92
(95% CI 0.88, 0.96) for the analysis of complete cases (with a shrinkage
factor of 0.91), and 0.88 (95% CI 0.84, 0.92) for themodel usingmultiple
imputation (Fig. 2B). Again adding TUBB6 made little difference, de-
creasing the AUC by 0.001. We report coefﬁcients for Model 1 based
on the multiple imputation dataset in Supplementary Table 3A and for
Model 2 in Supplementary Table 3B. When considered together in the
panel, allmarkers other thanWIF1 showed signiﬁcant independent pre-
dictive value.
The predictive model to discriminate samples where there is
methylation in the background mucosa (the matched non-neoplastic
samples, model 3) from controls had poorer discrimination,with an op-
timism adjusted AUC of 0.66 (95% CI 0.59, 0.73) for the complete case
model (shrinkage factor 0.91), and 0.68 (95% CI 0.62, 0.73) for the
model using multiple imputation (Fig. 2C). We report coefﬁcients for
Model 3 based on the multiple imputation dataset in Supplementary
Table 3C. For SFRP5 and SOX7 lower levels of methylation were associ-
ated with neoplastic change in background mucosa. When considered
together only APC1A and SOX7 showed signiﬁcant independent predic-
tive value.
The calibration plot for Model 1 after multiple imputation suggested
that our ﬁnal model for neoplasia detection after multiple imputation
was reasonably well calibrated, with slight overestimation of probabil-
ity at lower risk and overestimation at higher risk (Supplementary
Fig. 3).Patients with neoplasia
n (%age)
Patients without neoplasia
(control) n (%age)
Total n (%age)
(n = 113) (n = 343) (N = 456)
23 (20%) 56 (16%) 79 (17%)
17 (15%) 61 (18%) 78 (17%)
67 (59%) 203 (59%) 270 (59%)
6 (5%) 23 (7%) 29 (6%)
75 (66%) 197 (57%) 272 (60%)
7 (6%) 9 (2%) 16 (4%)
22 (19%) 125 (36%) 147 (32%)
9 (8%) 12 (3%) 21 (5%)
100 (88%) 293 (85%) 393 (86%)
8 (7%) 46 (13%) 54 (12%)
5 (4%) (1%) 9 (2%)
85 (75%) 249 (73%) 334 (73%)
4 (4%) 20 (6%) 24 (5%)
24 (21%) 74 (22%) 98 (21%)
83 (73%) 257 (75%) 340 (75%)
6 (5%) 6 (2%) 12 (3%)
17 (15%) 13 (4%) 30 (7%)
7 (6%) 67 (20%) 74 (16%)
of epigenetic markers to identify colitis associated cancer: Results of
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Table 3
Distribution and comparison of methylation markers by sample type.
Biomarker Geometric mean (95% Conﬁdence interval) Ratio of geometric means
(95% conﬁdence interval); P-Valuea
Neoplastic (n = 113) Matched non-neoplastic
(n = 113)
Control (n = 343) Neoplastic vs. control Non-neoplastic
vs. control
sFRP2 22.1 (19.7, 24.9) 14.0 (12.8, 15.4) 14.1 (13.4, 14.9) 1.57 (1.40, 1.76) 0.99 (0.89, 1.11)
(n = 105) (n = 106) (n = 303) P b 0.0001 P = 0.92
sFRP4 44.7 (42.1, 47.5) 34.4 (31.8, 37.2) 32.0 (31.0, 33.1) 1.40 (1.31, 1.49) 1.07 (1.00, 1.15)
(n = 108) (n = 109) (n = 312) P b 0.0001 P = 0.057
WIF1 21.6 (18.6, 25.2) 12.8 (11.1, 14.8) 13.9 (12.8, 15.0) 1.56 (1.33, 1.83) 0.93 (0.79, 1.08)
(n = 104) (n = 105) (n = 292) P b 0.0001 P = 0.33
APC1A 2.92 (2.37, 3.60) 2.54 (2.16, 3.00) 1.99 (1.83, 2.17) 1.47 (1.22, 1.77) 1.28 (1.07, 1.52)
(n = 102) (n = 102) (n = 297) P = 0.0001 P = 0.006
APC2 35.4 (32.1, 39.0) 22.3 (20.4, 24.4) 20.2 (18.9, 21.5) 1.76 (1.55, 1.99) 1.11 (0.98, 1.26)
(n = 111) (n = 106) (n = 322) P b 0.0001 P = 0.12
sFRP1 35.7 (30.5, 41.9) 24.1 (21.7, 26.7) 25.1 (23.2, 27.1) 1.42 (1.21, 1.67) 0.96 (0.82, 1.13)
(n = 39) (n = 29) (n = 118) P b 0.0001 P = 0.62
sFRP5 7.14 (5.75, 8.87) 4.90 (4.08, 5.90) 6.40 (5.64, 7.27) 1.12 (0.87, 1.43) 0.77 (0.60, 0.98)
(n = 102) (n = 95) (n = 275) P = 0.38 P = 0.03
MINT1 4.14 (3.32, 5.16) 3.40 (2.87, 4.04) 3.13 (2.82, 3.48) 1.32 (1.06, 1.64) 1.09 (0.89, 1.33)
(n = 73) (n = 70) (n = 200) P = 0.012 P = 0.42
RUNX3 8.73 (7.15, 10.7) 7.58 (6.37, 9.02) 7.44 (6.68, 8.29) 1.17 (0.94, 1.46) 1.02 (0.83, 1.25)
(n = 87) (n = 97) (n = 248) P = 0.15 P = 0.86
SOX7 5.70 (4.60, 7.06) 3.92 (3.41, 4.51) 5.41 (4.88, 5.99) 1.05 (0.85, 1.30) 0.73 (0.60, 0.87)
(n = 100) (n = 106) (n = 280) P = 0.63 P = 0.001
TUBB6 12.2 (10.5, 14.2) 8.04 (6.93, 9.34) 9.34 (8.52, 10.23) 1.31 (1.10, 1.56) 0.86 (0.72, 1.03)
(n = 108) (n = 95) (n = 292) P = 0.003 P = 0.11
a Computed from a 2-sample t-test on log transformed data.
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We identiﬁed the value of the predictive model corresponding to a
likelihood ratio of at least 6, to identify thresholds which would have a
positive predictive value of at least 20% when disease prevalence was
4%. This corresponded to a threshold of 0.40 for Model 1, 0.28 for
Model 2, and 0.50 forModel 3. Sensitivity and speciﬁcity (with 95% con-
ﬁdence intervals) at this threshold were 58.4% (48.8%, 67.6%) and
90.38% (86.8%, 93.3%) for Model 1, 79.5% (71.0%, 86.6%) and 86.9%
(82.8%, 90.3%) for Model 2 and 7.1% (3.1%, 13.5%) and 98.8% (97.0%,
99.7%) for Model 3.
To achieve a sensitivity of at least 90%: Model 1 would use a thresh-
old of 0.11with a speciﬁcity of 46.4% (41.1%, 51.8%) and positive predic-
tive value of 6.6% (5.9%, 7.3%); Model 2 would use a threshold of 0.11
with a speciﬁcity of 68.2% (63.0%, 73.1%) and positive predictive value
of 10.7% (9.11%, 12.3%); and Model 3 would use a threshold of 0.19
with a speciﬁcity of 27.1% (22.5%, 32.1%) and positive predictive value
of 4.9% (4.5%, 5.3%).3.4. Models for missing data
ForModel 1, to providemodels for scenarioswhere data on less than
ﬁve of the chosen biomarkers amplify, separate models accounting for
all possible scenarios of at least three biomarkers were created through
re-analysis of the multiple imputation model with reduced sets ofTable 4
Estimates of discrimination, optimism and shrinkage for ﬁtted models.
Modela Optimismb Shrinkageb Complete case
AUC (95% CI)
Compl
optimi
Model 1 0.012 0.93 0.871 (0.822, 0.919) 0.859 (
with TUBB6 0.015 0.91 0.875 (0.826, 0.923) 0.860 (
Model 2 0.012 0.91 0.930 (0.892, 0.967) 0.918 (
with TUBB6 0.015 0.88 0.932 (0.894, 0.970) 0.917 (
Model 3 0.021 0.90 0.682 (0.614, 0.750) 0.661 (
a Model 1 compared neoplasia with control; Model 2 compared dysplasia with control; Mod
b Optimism and shrinkage were estimated from internal validation using bootstrap samplin
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cients for which are reported in Supplementary Table 4.
4. Discussion
In this study we have demonstrated that a ﬁve marker methylation
marker panel accurately predicts ulcerative colitis associated dysplasia
and invasive neoplasia from formalin ﬁxed mucosal biopsies taken at
endoscopy, both dysplastic and “normal” mucosa within the potential
ﬁeld of epigenetic change. The generalisability of these ﬁndings is in-
creased through evaluation across a diverse population. The study has
also identiﬁed a second marker panel found in the background mucosa
that is (moreweakly) associatedwith neoplastic change. Our panels uti-
lise epigenetic biomarkers, which are emerging as a reproducible
method of quantifying disease risk in a population and suggest that
these markers may add value to endoscopic detection of colitis associ-
ated neoplasia.
Speciﬁc patterns of methylation change have been observed in colo-
rectal cancer [24] as well as speciﬁc changes observed in the transition
from dysplastic colorectal adenoma to malignant adenocarcinoma [25]
suggesting that methylation has good sensitivity as a biomarker of dis-
ease. To our knowledge, this is the ﬁrst multiplex methylation bio-
marker panel in colorectal cancer.
Other cancer types have demonstrated potential utility of methyla-
tion analysis in screening for invasive disease. The UroMark study [26]
investigated the utility of a multiplex bisulphite PCR amplicon nextete case adjusted for
sm AUC (95% CI)
Multiple imputation
AUC (95% CI)
Multiple imputation adjusted
for optimism AUC (95% CI)
0.810, 0.907) 0.845 (0.799, 0.891) 0.833 (0.787, 0.879)
0.811, 0.908) 0.848 (0.802, 0.894) 0.833 (0.787, 0.879)
0.880, 0.955) 0.892 (0.849, 0.934) 0.880 (0.837, 0.922)
0.879, 0.955) 0.894 (0.852, 0.937) 0.879 (0.837, 0.922)
0.593, 0.729) 0.696 (0.640, 0.751) 0.675 (0.619, 0.730)
el 3 compared matched non-neoplastic with control.
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6 A.D. Beggs et al. / EBioMedicine xxx (2018) xxxgeneration sequencing in the detection of muscle invasive bladder can-
cer in voided urine. Using a 150 marker panel based on differentially
methylated CpG loci in a discovery study, they validated their marker
panel in a cohort of 274 patients with muscle invasive bladder cancer,
ﬁnding an overall AUC = 0.97. A signiﬁcant advantage of their cohort
was the ability to develop a marker panel based on a large sample
number epigenome wide association study, an approach that might be
appropriate in UC associated dysplasia, which has a heterogeneous ge-
netic proﬁle.Fig. 2.ROC curves forﬁnalﬁtted predictivemodels (aftermultiple imputation). A=Model
1 Neoplasia vs control; B = Model 2 Dysplasia vs control; C = Model 3 Matched non-
neoplastic vs control. X-axis = 1-speciﬁcity; Y-axis = Sensitivity.
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marker panel for the detection of disease and multiple marker panels
using several different technologies have been developed across
multiple disease types that have reached this target [27–29]. The AUC
for detection of colitis associated neoplasia suggests this is a reliable
test for neoplasia, however we are seeking to enhance detection, not re-
place colonoscopy. Ultimately it is the early detection of occult disease
thatwill determine the value of this assay, and that requires prospective
evaluation, which is already underway.
It is likely with more extensive epigenetic analysis of this retrospec-
tive cohort we could enhance our observed AUC level. The study has
established that a reliable and robust assay can be developed for these
patients. We are currently developing an NGS based multiplex assay
to increase clinical utility. Whilst we under recruited tumour blocks
(113 rather than the planned 160) this still provided over 20 events
per variable for generating our 5-marker models, but will have in-
creased the maximum 95% conﬁdence interval width for sensitivity by
3%. The study was however carried out on a genetically and geographi-
cally diverse population, supporting the generalisability of our ﬁndings.
This study has also developed a novel marker set for predicting the
presence of co-existing neoplasia from analysis of the background mu-
cosa. Unsurprisingly, the AUC value for this is signiﬁcantly lower, and
the test therefor less robust. But the impact of these markers can only
be determined in a longitudinal analysis. These methylation changes
are present in a subset of the UC population, without associated neopla-
sia. Follow up of these patients will be required to determine whether
this represents a high risk population for whom therapeutic cancer pre-
vention strategies can be developed.
Three markers (SFRP1, MINT1 and RUNX3) were not taken forward
due to poor ampliﬁcation rates during PCR, which we hypothesised
was because of the high GC content of these regionsmaking primer de-
sign difﬁcult across FFPE derived DNA. Also, WIF1 methylation was
found not to contribute to the disease model, presumably because be-
cause its methylation levels were similar to other genes that were
analysed within this study that are all modulators of theWnt signalling
pathway. We also noticed that the direction of methylation (towards
hypomethylation) differing for themarkers in model 3, we hypothesise
that this is because of the previously demonstrated “wave” of hypome-
thylation [30] that occurs as a precursor to invasive malignancy and
therefore should occur in the disease associated non-dysplastic mucosa
we sampled here.
This study has proposed a methylation marker panel developed
fromanalysed a retrospectivemulticentre cohort of ulcerative colitis pa-
tients with and without colitis associated dysplasia. We are now com-
pleting a prospective diagnostic accuracy study, of 820 UC patients
within a surveillance programme, to evaluate the diagnostic utility of
this panel test.
In conclusion, we have successfully developed a multiplex methyla-
tion marker panel for the detection of ulcerative colitis associated dys-
plasia and neoplasia which has validated in a retrospective cohort and
is currently being evaluated in the context of a prospective clinical trial.
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